Kava: Mechanisms, the Potentiation Thesis, and the Liver

Kava own mechanisms: the map the potentiation thesis is built on contested in vitro

The Oilahuasca reasoning is that if a preparation depends on an enzyme for its termination, then inhibiting that enzyme changes the preparation — the same logic that makes an orally inactive tryptamine orally active when MAO-A is blocked. Applied to kava, the reasoning needs the mechanism map first, and kava has an unusually crowded one. Kavain potentiates GABA-A receptors, with the functional characteristics and molecular mechanism worked out by Chua and colleagues; the other major kavalactones act on the same receptor. The kavalactones reversibly inhibit monoamine oxidase, reported in human platelets for MAO-B by Uebelhack and colleagues in 1998 and characterised kinetically across the major kavalactones by Prinsloo and colleagues in 2019. Yangonin binds CB1 at approximately 720 nM, reported by Ligresti and colleagues along with the observation that kavalactones interact with endocannabinoid-system enzymes. Kavain inhibits veratridine-activated voltage-gated sodium channels in rat cortical synaptosomes and reduces the depolarisation-evoked rise in intracellular calcium and glutamate release, both from Gleitz and colleagues. And kava pyrones inhibit monoamine uptake, reported by Seitz and colleagues. There is also a clinical signal for the intended effect: randomised placebo-controlled trial evidence in generalised anxiety disorder, including Sarris and colleagues 2013.

Contested — caveat. The FAAH and MAGL inhibition claim is the weakest link in this map: it is carried in the operator corpus as established and the primary support located is the Ligresti kavalactone work, which is in vitro. The frequently repeated claim that methysticin and dihydromethysticin are potent CYP3A4 and CYP2C9 inhibitors is in tension with the one in-vivo human probe study available, which found no significant CYP3A4 or CYP2D6 effect for kava and did find CYP2E1 inhibition. Prefer the in-vivo result.

Sources: Chua HC 2016 · Uebelhack R 1998 · Prinsloo D 2019 · Ligresti A 2012 · Gleitz J 1995 · Gleitz J 1996 · Seitz U 1997 · Gurley BJ 2005 · Sarris J 2013 · Van Kush Family Research Institute 2026*

The potentiator categories contested in vitro

The operator datasheet organises candidate potentiators by which of kava mechanisms they target. Presented here as categories with their pharmacology and evidence level, and deliberately without doses, timings, combinations or preparation methods. Category one is GABA-transaminase inhibition, aimed at the enzyme that degrades GABA rather than at the receptor: rosmarinic acid from lemon balm is the flagship, and Awad and colleagues measured GABA-transaminase inhibition for traditionally used anxiolytic botanicals including Melissa officinalis, reporting rosmarinic acid activity in the fractions tested. Valerenic acid from valerian both potentiates GABA-A directly, characterised by Khom and colleagues with subunit specificity and confirmed in vivo by Benke and colleagues, and is claimed in the corpus to inhibit GABA-transaminase. Baicalin and baicalein from Scutellaria are GABA-A positive allosteric modulators in the same category. Category two is CYP inhibition as a bioavailability strategy — piperine, grapefruit furanocoumarins, curcuminoids — which is covered on the piperaceae page and the cyp450 shelf and is the category with the largest hazard, treated separately below. Category three is FAAH inhibition, the natural-inhibitors table. Category four is endocannabinoid reuptake inhibition, principally guineensine. Category five is CB2 agonism, principally β-caryophyllene.

Contested — caveat. Every compound in this table faces the same in-vitro-to-human gap set out on the natural-inhibitors page. The GABA-transaminase inhibition figures in particular are extract and fraction assays, and the claim that valerenic acid inhibits GABA-transaminase is carried from the operator corpus rather than from a located primary source. No combination in this table has been tested as a combination in humans.

Sources: Awad R 2007 · Khom S 2007 · Benke D 2009 · Bhardwaj RK 2002 · Pattanaik S 2009 · Volak LP 2008 · Thors L 2008 · Thors L 2010 · Wu H 2013 · Nicolussi S 2014 · Gertsch J 2008 · Van Kush Family Research Institute 2026*

SAFETY: the kava hepatotoxicity signal contested human data

This section is not an afterthought and should be read before anything above it is acted on. From the late 1990s a series of cases of severe liver injury associated with kava-containing products emerged in Europe, including hepatitis, cholestatic injury, fulminant hepatic failure and transplantation. Regulators in Germany, Switzerland, the United Kingdom, France and elsewhere withdrew or restricted kava products from 2002 onward. The literature since has been a sustained argument about causation rather than a settled verdict, and the argument matters because each candidate explanation implies a different conclusion about traditional aqueous preparation. Teschke reviewed the pathogenetic aspects in 2010, compared aqueous, ethanolic and acetonic extracts and kava-herb mixtures in 2009, and with Sarris and Lebot proposed a standardisation plan in 2011. Four variables recur: cultivar, with the distinction between noble kava and the tudei and wichmannii types that carry higher flavokavain content, quantified across cultivars by Lebot and colleagues using HPTLC; plant part, with aerial parts, stem peelings and bark implicated rather than the peeled root traditionally used; extraction solvent, with acetonic and ethanolic extracts carrying a different compound profile, including more of the lipophilic flavokavains, than the traditional cold-water preparation; and co-medication or co-ingestion, including alcohol and hepatically cleared drugs. The flavokavain B hypothesis is the leading mechanistic candidate: Zhou and colleagues reported that flavokavain B induces glutathione-sensitive oxidative stress in hepatocytes through IKK/NF-κB and MAPK signalling and is the hepatotoxic constituent of kava root. That is real mechanistic work and the causal attribution is still contested — idiosyncratic host factors, CYP2D6 poor-metaboliser status, glutathione depletion and product adulteration have all been proposed, the case series are heterogeneous and many cases carry confounders. What is NOT contested is that the signal exists.

• Cases include fulminant hepatic failure and transplantation; European withdrawals from 2002.
• Noble versus tudei or wichmannii cultivar is a measurable chemical difference, not folklore.
• Aerial parts and stem peelings are implicated; traditional use is the peeled root.
• Acetonic and ethanolic extracts differ in profile from traditional aqueous preparation.
• Flavokavain B is the leading mechanistic candidate and the causal attribution remains contested.

Contested — caveat. The causal mechanism of kava hepatotoxicity is genuinely unresolved. Flavokavain B has the best mechanistic support but the epidemiology is heterogeneous, confounded by co-medication and alcohol, and inconsistent about cultivar and preparation. Treating any single explanation as established — including the reassuring versions, such as "traditional aqueous noble-root preparation is safe" — goes beyond the evidence.

Sources: Teschke R 2010 · Teschke R 2009 · Teschke R 2011 · Lebot V 2014 · Zhou P 2010

SAFETY: why stacking CYP inhibitors onto kava is the specific hazard human data

Here is the collision this whole page exists to name. The potentiation strategy category two is: inhibit the cytochromes so the kavalactones are cleared more slowly and reach higher levels. The hepatotoxicity signal is: kava, or a constituent of kava, loads the liver. Those two statements combined describe deliberately slowing the clearance of the very compound implicated in the organ injury, in the organ where the injury occurs, using agents (piperine, furanocoumarins, curcuminoids) that are themselves cleared hepatically. The mechanism is additive from both directions: higher and longer exposure to the hepatotoxic candidate, and reduced metabolic capacity to handle it. There is no clinical study of this combination because nobody would design one. The interaction engine in this corpus treats kava as carrying a hepatotoxicity role and treats piperine, grapefruit and curcuminoids as CYP inhibitors, and the additive-hepatotoxicity plus reduced-clearance pattern is exactly the kind of stack that engine is built to flag. It is worth adding that the direction of the CYP effect for kava itself is not what the popular account says: the one in-vivo human probe study found kava inhibited CYP2E1 and did not significantly move CYP3A4 or CYP2D6, so a potentiation model built on kava as a CYP3A4 inhibitor is building on a claim the human data do not support.

• The potentiation mechanism and the injury mechanism act on the same organ in the same direction.
• The potentiators are themselves hepatically cleared, so the stack competes for the same capacity.
• No human study of the combination exists; the absence of data is not reassurance.
• Kava own CYP profile in vivo (CYP2E1 inhibition, no significant CYP3A4 or CYP2D6 effect) contradicts the popular potentiation model.

Sources: Teschke R 2010 · Teschke R 2009 · Gurley BJ 2005 · Bhardwaj RK 2002 · Volak LP 2008

SAFETY: additive CNS depression, and the MAOI problem passionflower introduces contested human data

Two more hazards, both pharmacodynamic rather than hepatic. First, additive central depression. Kavain and the other kavalactones are positive modulators at GABA-A, the same receptor complex that benzodiazepines, alcohol, barbiturates and Z-drugs act on, and several of the proposed potentiators (valerenic acid, baicalein, apigenin from chamomile) act at that receptor or on GABA availability as well. Adding kava to alcohol, a benzodiazepine, or an opioid is additive on sedation and on respiratory drive by way of the opioid or alcohol component, and the whole potentiation framing is designed to increase that load rather than reduce it. Second, the monoamine oxidase problem. The kavalactones themselves reversibly inhibit MAO. Passionflower is on the potentiator list in the source datasheet specifically because of a claimed MAOI quality attributed to harmala alkaloids (harmine and harmaline), and if that is correct then a stack containing passionflower plus a reversible-MAO-inhibiting botanical carries the two MAOI hazards the corpus already documents at length: serotonin toxicity when combined with anything serotonergic, and the dietary tyramine pressor response. The harmala content of Passiflora incarnata is itself contested — reported at trace levels and disputed — which makes this a hazard to flag rather than to quantify. The correct handling is that a stack should not be built on an unquantified MAOI, in either direction: not as a potentiation mechanism, and not as a dismissed risk.

Contested — caveat. The harmala-alkaloid content of Passiflora incarnata is disputed in the literature and is reported at trace levels where reported at all; the herraiz2010 citation establishes the MAO-inhibitory pharmacology of the beta-carbolines themselves, in Peganum harmala, not their presence at active levels in passionflower. Treat the passionflower MAOI claim as unquantified in both directions.

Sources: Chua HC 2016 · Prinsloo D 2019 · Uebelhack R 1998 · Herraiz T 2010 · Van Kush Family Research Institute 2026*

The forum-sourced claims, labelled contested anecdotal

Part of the source datasheet reconstructs a 2020 KavaForums community thread, and several of its most quotable lines are anecdotal user reports rather than findings. They are recorded here with that provenance visible, because the value of the thread is ethnographic — it documents what a community of practice believes and does — and its evidentiary weight for a pharmacological claim is nil. Raw garlic described as the strongest potentiator I have ever experienced; hot herbal teas kick it into high gear; the best potentiator for kava is more kava, referring to a reported reverse-tolerance or accumulation effect; skullcap makes the effect smoother, takes the edge off; kanna, blue lotus and California poppy increasing euphoria. Each of these is a single-person subjective report from an online forum. Some have a plausible mechanism behind them (garlic organosulfur compounds do affect CYP enzymes; hot fluid changes gastric emptying and splanchnic blood flow) and a plausible mechanism is not evidence for the effect. Kanna is additionally worth flagging as a serotonergic agent, which makes its casual inclusion in a stack containing any MAO inhibitor a serotonin-toxicity question rather than a euphoria question.

• Raw garlic as the strongest potentiator: anecdotal, single reporter, 2020 forum thread.
• Hot tea kicks it into high gear: anecdotal; plausible mechanism is gastric emptying, not pharmacology.
• The best potentiator for kava is more kava (reverse tolerance): folk observation, mechanism unestablished.
• Kanna, blue lotus, California poppy for euphoria: anecdotal, and kanna carries a serotonergic interaction question.

Contested — caveat. Sourced to a 2020 KavaForums community discussion thread as reconstructed in the operator datasheet; the thread was not independently retrieved during compilation. These are subjective user reports and carry no evidentiary weight for a pharmacological claim.

Sources: KavaForums community discussion thread 2020* · Van Kush Family Research Institute 2026*

What this page deliberately omits, and where the arithmetic lives human data

The source datasheet contains a preparation-and-timing section — what to take before, what goes in the preparation, what to take after — and it is not reproduced here or anywhere on this shelf. This shelf describes mechanisms and hazards. The handling arithmetic for a compound already obtained, which is a legitimate and load-bearing part of harm reduction, belongs on the formulation shelf: dose-per-unit calculation, homogeneity, titration from a low starting point, and the specific problem of a preparation whose strength varies between batches. The relevant items for anyone reading this page are the titration principle and the dose-arithmetic page, plus the interaction corpus for the CYP and MAOI questions. What this page will say is that the three highest-value pieces of information for a kava user are not potentiation-related at all: cultivar (noble versus tudei), plant part (peeled root versus aerial parts), and preparation type (traditional aqueous versus organic-solvent extract) — because those are the three variables the hepatotoxicity literature keeps returning to.

Sources: Teschke R 2011 · Lebot V 2014 · Teschke R 2009